Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 1262-1268, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Menéndez-Fraga, P.
Right arrow Articles by Cannata-Andía, J. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Menéndez-Fraga, P.
Right arrow Articles by Cannata-Andía, J. B.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1998;44:1262-1268.)
© 1998 American Association for Clinical Chemistry, Inc.

Drug Monitoring and Toxicology

Low percentage of aluminoxamine and ferrioxamine in uremic serum after desferrioxamine administration

Pilar Menéndez-Fraga1, Jose L. Fernández-Martín1, Elisa Blanco-González2, and Jorge B. Cannata-Andía1,a

1 Bone and Mineral Research Unit, Hospital Central de Asturias, Instituto Reina Sofía de Investigación Nefrológica, Julián Clavería s/n, Oviedo 33006, Spain.

2 Department of Physical and Analytical Chemistry, Faculty of Chemistry, University of Oviedo, Oviedo 33006, Spain.
a Author for correspondence. Fax 34-8-5106142; e-mail cannata{at}hca.es.

HPLC was used to study the effectiveness of two different desferrioxamine (DFO) administration strategies (15 mg/kg DFO, 1 h or 44 h before dialysis) on generation of aluminoxamine and ferrioxamine in five hemodialysis patients. The percentage of ultrafilterable aluminum and iron in these patients was also investigated by electrothermal atomic absorption spectrometry. The administration of DFO in both schemes increased the ultrafilterable serum aluminum concentrations from a mean of 17.1 ± 1.6% to a mean of 75.7 ± 14.1%. However, 1 h after DFO infusion, only 38.8 ± 7.7% of the total serum aluminum was bound to DFO; 44 h after DFO infusion, only 15.8 ± 8.0% was bound. Similar results were obtained for ferrioxamine. These results suggest that the ultrafilterable serum fraction contains aluminum and iron chelated by DFO and by DFO metabolites, which retain similar metal-chelating abilities.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.